Connatal localized neuroblastoma: The case to delay treatment

Cancer

Volumn 77, Issue 7, 1996, Pages 1395-1401

  Kerbl, Reinhold ^a   Urban, Christian E ^a   Lackner, Herwig ^a   Höfler, Gerald ^b   Ambros, Inge M ^c   Ratschek, Manfred ^b   Ambros, Peter F ^c  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

^c CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

Author keywords

connatal neuroblastoma; delayed treatment; incidental diagnosis; prognostic factors; sonography; spontaneous regression

Indexed keywords

ARTICLE; CANCER LOCALIZATION; CASE REPORT; EARLY DIAGNOSIS; FETUS; FETUS ECHOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; NEUROBLASTOMA; NEWBORN; PREDICTION; PRIORITY JOURNAL; TREATMENT PLANNING; TUMOR REGRESSION;

ADRENAL GLAND NEOPLASMS; HUMANS; INFANT; INFANT, NEWBORN; NEOPLASM REGRESSION, SPONTANEOUS; NEUROBLASTOMA; PROGNOSIS; TIME FACTORS;

EID: 0029923774     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960401)77:7<1395::AID-CNCR26>3.0.CO;2-W     Document Type: Article

References (51)

1. Carlsen NL. Neuroblastoma: epidemiology and pattern of regression. Problems in interpreting results of mass screening. Am J Pediatr Hematol Oncol 1992; 14:103-10.
2. D'Angio GJ, Evans AE, Koop CE. Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1971; 1:1046-9.
3. Shimotake T, Iwai N, Tokiwa K, Deguchi E, Sawada T, Fushiki S. Increased numbers of argyrophilic nucleolar organizer regions between primary and metastatic sites predict tumor progression in stage IV and IV-S neuroblastoma. Cancer 1994; 73:3103-7.
4. Suarez A, Hartmann O, Vassal G, Giron A, Habrand JL, Valteau D, et al. Treatment of stage IV-S neuroblastoma: a study of 34 cases treated between 1982 and 1987. Med Pediatr Oncol 1991; 19:473-7.
5. Bourhis J, Dominici C, McDowell H, Raschella G, Wilson G, Castello MA, et al. N-myc genomic content and DMA ploidy in stage IV-S neuroblastoma. J Clin Oncol 1991; 9:1371-5.
6. Kushner BH, LaQuaglia MP, Ambros PF, Bonilla MA, Gerald WL, Rosenfield NS, et al. Survival from locally invasive or metastatic neuroblastoma without cytotoxic therapy. Proc Am Soc Clin Oncol 1993; 12:413.
7. Matthay KK, Sather HN, Seeger RC, Haase GM, Hammond GD. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol 1989; 7:236-44.
8. Knudson AG, Meadows AT. Regression of neuroblastoma IV-S: a genetic hypothesis. N Engl J Med 1980; 302:1254-5.
9. Kogner P, Barbany G, Dominici C, Castello MA, Raschella G, Persson H. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res 1993; 53:2044-50.
10. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993; 328:847-54.
11. Ambros IM, Ambros PF. Schwann cells in neuroblastoma. Eur J Cancer 1995; 31A:429-34.
12. Ambros PF, Ambros IM, Strehl S, Bauer S, Luegmayr A, Kovar H, et al. Regression and progression in neuroblastoma. Does genetics predict tumour behaviour? Eur J Cancer 1995; 31A:510-5.
13. Huddart S, Mann J, Stevens MCG, Gornall P, Corkery JJ, Spooner D, et al. Neuroblastoma diagnosed antenatally: a treatment dilemma with implications for screening. Med Pediatr Oncol 1992; 20:156-61.
14. Matsumura M, Tsunoda A, Nishi T, Nishihira H, Sasaki Y. Spontaneous regression of neuroblastoma detected by mass screening [letter]. Lancet 1991; 338:447-8.
15. Dominici C, Andersen RA, Berthold F, Brodeur GM, Castel V, Castello MA, et al. Timing of delivery and early surgical management after prenatal ultrasonographic detection of neuroblastoma. Med Pediatr Oncol 1995; 25:242.
16. Carlsen NL. How frequent is spontaneous remission of neuroblastoma? Implications for screening. Br J Cancer 1990; 61:441-6.
17. Hayashi Y, Hanada R, Yamamoto K. Biology of neuroblastomas in Japan found by screening. Am J Pediatr Hematol Oncol 1992; 14:342-7.
18. Murphy SB, Cohn SL, Craft AW, Woods WG, Sawada T, Castleberry RP, et al. Do children benefit from mass screening for neuroblastoma? Lancet 1991; 337:344-6.
19. Parker L, Craft AW. Neuroblastoma screening: more questions than answers? [editorial]. Eur J Cancer 1991; 27:682-3.
20. Sawada T. Past and future of neuroblastoma screening in Japan. Am J Pediatr Hematol Oncol 1992; 14:320-6.
21. Schweizer D, Ambros PF. Chromosome banding. Stain combinations for specific regions. In: Gosden JR, editor. Methods in molecular biology. Volume 29. Chromosome analysis protocols. Totowa: Humana Press, 1994:97-112.
22. Strehl S, Ambros PF. Fluorescence in situ hybridisation combined with immunohistochemistry for highly sensitive detection of chromosome 1 aberrations in neuroblastoma. Cytogenet Cell Genet 1993; 63:24-8.
23. Evans AE, D'Angio GJ, Randolph J. A proposed staging for children with neuroblastoma. Cancer 1971; 27:374-8.
24. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castleberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treat-ment. J Clin Oncol 1993; 11:1466-77.
25. Shimada H, Chatten J, Newton WA, Sachs N, Hamondi AB, Chiba T, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastoma. J Natl Cancer Inst 1984; 405-16.
26. Joshi W, Cantor AB, Brodeur GM, Look AT, Shuster JJ, Altshuler G, et al. Correlation between morphologic and other prognostic markers of neuroblastoma. Cancer 1993; 71:3173-81.
27. Beckwith JB, Perrin EV. In situ neuroblastomas: a contribution to the natural history of neural crest tumors. Am J Pathol 1963; 43:1089-104.
28. Ikeda Y, Lister J, Bouton JM, Buyukpamukcu M. Congenital neuroblastoma, neuroblastoma in situ, and the normal fetal development of the adrenal. J Pediatr Surg 1981; 16:636-44.
29. Brodeur GM, Castleberry RP. Neuroblastoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. 2nd edition. Philadelphia: JB Lippincott, 1989:739-67.
30. Bolande RP. The spontaneous regression of neuroblastoma. Experimental evidence for a natural host immunity. Pathol Annu 1991; 26:187-99.
31. Brodeur GM, Azar C, Brother M, Hiemstra J, Kaufman B, Marshall H, et al. Neuroblastoma. Effect of genetic factors on prognosis and treatment. Cancer 1992; 70:1685-94.
32. Di Martino D, Ponzoni M, Cornaglia-Ferraris P, Tonini GP. Different regulation of mid-size neurofilament and N-myc mRNA expression during neuroblastoma cell differentiation induced by retinoic acid. Cell Mol Neurobiol 1990; 10:459-70.
33. Suzuki T, Bogenmann E, Shimada H, Stram D, Seeger RC. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 1993; 85:377-84.
34. Pritchard J, Hickman JA. Why does 4s neuroblastoma regress spontaneously? Lancet 1994; 344:869-70.
35. Goodman SN. Neuroblastoma screening data. An epidemiologic analysis. Am J Dis Child 1991; 145:1415-22.
36. Woods WG, Tuchman M, Bernstein ML, Leclerc JM, Brisson L, Look T, et al. Screening for neuroblastoma in North America. 2-year results from the Quebec project. Am J Pediatr Hematol Oncol 1992; 14:312-9.
37. Kerbl R, Urban C, Starz I, Ambros EM, Strehl S, Kovar H, et al. Neuroblastoma with N-myc amplification detected by urine mass screening in infants after the sixth month of life. Med Pediatr Oncol 1993; 21:625-6.
38. Hachitanda Y, Ishimoto K, Jun-ichi H, Shimada H. One hundred neuroblastomas detected through a mass screening system in Japan. Cancer 1994; 74:3223-6.
39. Kusafuka T, Nagahara N, Oue T, Imura K, Nakamura T, Kobayashi Y, et al. Unfavorable DNA ploidy and Ha-ras p21 findings in neuroblastoma detected through mass screening. Cancer 1995; 76:695-9.
40. Nishi M, Miyake H, Takeda T, Yonemori H, Hanai J, Kikuchi Y, et al. Cases of spontaneous regression and true patients detected in mass screening for neuroblastoma. Int J Pediatr Hematol/Oncol 1995; 1:557-63.
41. Nishi M, Miyake H, Takeda T, Yonemori H, Hanai J, Kikuchi Y, et al. A trial to discriminate spontaneous regression from non-regression cases during mass screening for neuroblastoma. Jpn J Clin Oncol 1994; 24:247-51.
42. Berthold F, Kassenbohmer R, Zieschang J. Multivariate evaluation of prognostic factors in localized neuroblastoma. Am J Pediatr Hematol Oncol 1994; 16:107-15.
43. Oppedal BR, Storm-Mathisen I, Lie SO, Brandtzaeg P. Prognostic factors in neuroblastoma. Clinical, histopathologic, and immunohistochemical features and DNA ploidy in relation to prognosis. Cancer 1988; 62:772-80.
44. Leone A, Seeger RC, Hong CM, Hu YY, Arboleda MJ, Brodeur GM, et al. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastoma. Oncogene 1993; 8:855-66.
45. Look TA, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991; 9:581-91.
46. Huddart SN, Mann JR, McGukin AG, Corbett R. MYCN amplification by differential PCR. Pediatr Hematol Oncol 1993; 10:31-4.
47. Losty P, Quinn F, Breatnach F, O'Meara A, Fitzgerald RJ. Neuroblastoma - a surgical perspective. Eur J Surg Oncol 1993; 19:33-6.
48. Dominici C, Raschella G, Padula A, Clerico A, Fares C, Bartolozzi S, et al. Genomic characteristics in prenatally-detected neuroblastoma. Med Pediatr Oncol 1992; 20:424.
49. Dominici C, Berthold F, Brodeur GM, Castel V, Castello MA, Castleberry RP, et al. Prenatal neuroblastoma: a report by the Prenatal Neuroblastoma Study Group. Proc Am Assoc Cancer Res 1994; 35:239.
50. Ho PTC, Estroff JA, Kozakewich H, Shamberger RC, Lillehei CW, Grier HE, et al. Prenatal detection of neuroblastoma: a ten-year experience from the Dana-Farber Cancer Institute and Children's Hospital. Pediatrics 1993; 92:358-64.
51. Beck D, De Bernardi B, Michon J, Ambros PF. Phase II clinical trial of surgery as the only treatment for INSS stage 2 neuroblastoma (94.01 trial and study of the Localized Neuroblastoma European Study Group; SIOP 95.01 study). Med Pediatr Oncol 1995; 25:278.